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1. Introduction
Small molecule disease-modifying antirheumatic drugs (DMARDs) played a central role in
drug therapy for rheumatoid arthritis (RA) before biological preparations (biologics) came
into extensive use for the treatment of this disease. Unlike non-steroidal anti-inflammatory
drugs (NSAIDs) and steroids, which primarily alleviate the symptoms of RA such as pain
and inflammation, DMARDs are known to suppress the progression of RA through their ac‐
tion against immunological abnormalities.
To review the history of the clinical positioning of DMARD therapy, until the beginning of
the 1990s, DMARDs were used only in patients showing signs of disease progression (e.g.,
bone erosion) after NSAIDs or steroid treatment within the framework of pyramid therapy
[1]. During the 1990s through the 2000s, the strategy and goals of RA therapy have under‐
gone marked changes following the introduction of methotrexate (MTX) as another treat‐
ment option, the expansion of MTX as an anchor drug [2,3,4], endorsement of the usefulness
of combined drug therapy involving DMARDs [5], the introduction of biologics into RA
treatment [6,7,8], and other advances. In 2002, the American College of Rheumatology
(ACR) released its Guidelines on RA Management, clearly indicating DMARDs as first-line
drugs for the treatment of RA. As a result, NSAIDs and steroids came to be positioned as
auxiliary means of treating RA [9].
The small molecule DMARDs that have been used frequently in Western countries are MTX,
sulphasalazine (SASP), hydroxychloroquine (HCQ), leflunomide (LFN), and minocycline
(MIN). In Japan, where the repertoire of drugs clinically available differs from that in West‐
ern countries, HCQ and MIN are not indicated for RA under the national health policy, and
bucillamine (BUC) has been a more popular small molecule DMARD than these 2 drugs.
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The use of biologics such as TNF inhibitors began to spread around the world within several
years of their clinical introduction as drugs that exert rapid action and are expected to im‐
prove long-term prognosis and to allow patients with RA to maintain physical function [10].
During the 2000s, revisions of the guidelines on RA treatment and criteria for diagnosis of
RA were accelerated in various countries, with the goal of treatment shifting from symptom
control (anti-inflammatory analgesia) and delayed disease progression to achievement of
disease remission and suppression of disease progression. As an accumulation of clinical tri‐
al data became available revealing from a long-term perspective the advantageous effects of
biologics not found in small molecule DMARDs, including suppression of progression of
bone destruction and physical dysfunction [11,12], biologics began to replace small molecule
DMARDs, primarily in patients anticipated to have a poor prognosis and those with rapidly
advancing disease. In addition, introduction of biologics into therapy at an early stage of ac‐
tive RA has been recommended in some guidelines because of the benefits expected from
this kind of drug for maintaining long-term quality of life in many patients [13].
Nonetheless, there are still several open issues involved in the use of biologics, including:
1. presence of a considerable percentage of patients who fail to respond to treatment with
biologics[14],
2. heavy economic burdens for individuals and the community due to high drug prices
[15],
3. risk of serious adverse reactions (e.g., infection) in some patients [16,17], and so on.
These issues represent obstacles to the establishment of biologics as a predominant means of
treatment for RA. In recent years, several reports have been published in the United States
and Europe providing data intended to serve as evidence for the view that treatment with a
combination of 3 small molecule DMARDs is expected to improve long-term prognosis of
RA to an extent comparable with biologics. Following these reports, in Western countries,
the guidelines/guidance on RA treatment have been further reviewed, resulting in restate‐
ment of the position that small molecule DMARDs are first-line drugs, and a clear statement
that combination therapy with small molecule DMARDs should be tried before the therapy
with biologics [18]. This chapter will describe the popular small molecule DMARDs current‐
ly used for treatment of RA and present a discussion regarding the current position of small
molecule DMARDs in RA treatment guidelines/guidance, as well as its background. In addi‐
tion, 2 new small molecule DMARDs, tofacitinib and iguratimod, are discussed.
 
2. Popular small molecule DMARDs
DMARDs is the collective term for a set of drugs known to suppress the progression of RA
via action against immunological abnormalities. These drugs do not exhibit the rapid action
on symptoms, i.e., inflammation and pain, exerted by NSAIDs and steroids.
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DMARDs are additionally capable of delaying the progression of bone destruction, but it is
rare that remission of RA can be achieved by DMARD mono-therapy in patients with estab‐
lished RA. DMARDs are generally slow in action, taking 1 to 3 months until manifestation
of their effects. The response to these drugs varies greatly among individuals, and a number
of patients fail to respond to treatment with DMARDs. Furthermore, patients whose disease
activity is initially controlled by DMARDs sometimes cease to respond to the drugs (relapse)
during prolonged use. Another characteristic of DMARDs is a high incidence of adverse re‐
actions, with the incidence of adverse events with each DMARD being between 20% and
50%. If adverse reactions are mild, treatment with DAMARDs can be often continued by
means of dose reduction or symptomatic treatment, but the risk that patients will develop
life-threatening serious adverse reactions, including hematological disorders, renal disorder,
and interstitial pneumonia, is common.
Some DMARDs are immune suppressors that are also used for control of host rejection of
grafts and treatment of cancer, including MTX, LFN, tacrolimus (TAC), cyclosporine, aza‐
thioprine, and cyclophosphamide. The class also includes immune modulating agents, such
as SASP, BUC, d-penicillamine, gold compound, and others, as well as HCQ, an anti-malar‐
ia agent, and MIN, an antibiotic (Table1).
Here, the popular DMARDs used clinically are described. BUC is approved as a DMARD
for treatment of RA only in Japan and Korea, and currently, the use of BUC is almost exclu‐
sively confined to Japan, where this drug is still used in quantities as large as SASP, second
to MTX among the approved DMARDs.
 
3. Methotrexate (MTX)
MTX is a folic acid antagonist. The drug has been reported to exert immunosuppressive ac‐
tivity through its action (suppression of proliferation) on immune competent cells by means
of DNA synthesis inhibition, and to exert anti-inflammatory activity by inducing pooling of
adenosine [19]. Details are unknown about the mechanism of its antirheumatic activity, but
the drug has shown excellent efficacy and long duration, and it is the most frequently used
small molecule DMARD in the world as an anchor drug for RA treatment [3,4]. The most
recent guidelines recommend early initiation of treatment with MTX as a first-line drug in
patients with factors associated with poor prognosis such as positive ACPA, bone erosion,
extra-articular symptoms, or restricted physical function [18]. Among the antirheumatic
drugs, MTX tends to exert its effects relatively early (within 1 to 2 months) and these effects
include suppression of joint destruction [20,21].
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Table 1 summary of small molecule DMARDs
Adverse reactions to MTX include infection, stomatitis, glossitis, nausea, hepatic dysfunc‐
tion [22], and others. It is known that these adverse reactions are more likely to appear in
patients with compromised renal function and in elderly patients, and that they can be re‐
duced by concomitant use of folic acid or leucovorin [23,24,25]. Interstitial pneumonia and
bone marrow suppression are known as serious adverse reactions. Interstitial pneumonia
can develop suddenly and is sometimes intractable [26]. Marrow suppression involves im‐
paired hematopoiesis. Both of these reactions are serious and require hospitalization. As a
rule, MTX is administered once weekly via an oral or parenteral route at an initial dose level
of 7.5 to 15 mg, with the dose being gradually increased up to 25 mg/week if responses are
insufficient. In Japan, MTX is only administered orally, at an initial dose level of 6 mg/week.
The dose is gradually increased up to 16 mg if responses are insufficient. The weekly dose
level may be divided into 1 to 3 doses in 1 or 2 days. It is known that the effects of MTX are
strengthened by concomitant use of biologics [27].
4. Sulphasalazine (SASP)
This drug exerts action relatively rapidly (in 1 to 2 months) among the DMARDs. Like MTX,
SASP has been reported to exert anti-inflammatory activity by inducing pooling of adeno‐
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sine [28], and to have immunomodulating effects as well, e.g., suppression of antibody pro‐
duction [29]. The antirheumatic activity of SASP has not been sufficiently clarified, but
because it suppresses joint destruction [20], it is considered as an option for treatment of RA
with MTX. As compared to other DMARDs, SASP can be characterized by low nephrotoxici‐
ty, and the risk for teratogenicity in pregnant women is also considered to be lower with
SASP than with other DMARDs. Adverse reactions to SASP include liver disorder, drug
eruption, bone marrow disorders, and others. Because the incidence of gastrointestinal dis‐
orders as an adverse reaction is high with the bulk form of SASP, it is usually administered
in the form of an enteric-coated tablet for the treatment of RA. In Western countries, this
drug is usually recommended for treatment at a dose level of 2 to 3 mg/day, while in Japan,
the upper limit of the dose level is set at 1 mg/day.
5. Leflunomide (LFN)
LFN is a metabolic antagonist capable of suppressing the proliferation of T lymphocytes
through pyrimidine synthesis inhibition [20]. This drug has been reported to suppress joint
destruction. It is characterized by the long half-life of its active form. Adverse reactions to
LFN include infection, diarrhea, bone marrow disorders, hypertension, liver disorder, nau‐
sea, alopecia, and others. Interstitial pneumonia is an adverse reaction that requires utmost
caution and is potentially fatal. LFN has been reported to be teratogenic [30,31]. For a couple
planning pregnancy, it is necessary for both partners to take cholestyramine to eliminate the
active metabolites of LFN completely. Because of the long the half-life of the active metabo‐
lite in vivo, the drug is administered at a loading dose level (100 mg) for the first 3 days, fol‐
lowed by administration at a constant dose level (20 mg/day).
6. Hydroxychloroquine (HCQ)
HCQ was used as an anti-malaria agent before it was used as an antirheumatic drug [32].
The anti-malaria activity of HCQ is considered to have no relationship to its antirheumatic
activity. HCQ is believed to suppress antigen presentation by elevating the pH of the cyto‐
plasmic compartment of antigen-presenting macrophages [33]. More recently, it was report‐
ed that HCQ acts on the toll-like receptor to manifest effects on the immune system [34]. The
efficacy of HCQ is less than that of MTX, but HCQ has an excellent safety profile. For this
reason, HCQ is used for the treatment of mild RA [35]. Uncombined HCQ treatment does
not suppress the progression of bone destruction. Although the tolerability is high, adverse
reactions such as nausea and dizziness occasionally appear. Furthermore, the drug has a
high affinity for the retina and thus exerts high ocular toxicity. This is the reason that use of
the drug is not approved in some countries. Although retinal disorders induced by HCQ are
irreversible and if severe can lead to blindness, recovery from retinal disorders is sometimes
possible if they are detected early. HCQ is also used occasionally for treatment of articular
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and skin symptoms of SLE. For the treatment of RA, the drug is administered at a dose of
400 mg/day.
7. Minocycline (MIN)
The US Food and Drug Administration (FDA) has not approved MIN for treatment of RA.
However, a slow efficacy of this drug against RA has been shown in some double-blind tri‐
als [36,37,38,39]. Although the usefulness of this drug as a means of treatment for RA is low,
it has evidenced effects at early stages of RA. Compounds of the tetracycline family are
known to suppress matrix metalloproteinase [40], and this action is believed to suppress
narrowing of the joint space in patients with RA. The activity of MIN as an antibiotic is con‐
sidered to have no relationship to its antirheumatic activity.
8. Bucillamine (BUC)
BUC has been approved as a means of RA treatment in only Japan and Korea. As noted, at
present, its use is almost exclusively confined to Japan. BUC is used as frequently as SASP in
Japan, and this frequency of use is second to MTX. Its antirheumatic activity is slightly
stronger, that is comparable to or higher than, that of SASP [41,42]. For this reason, BUC is
used for treatment of mild to moderate RA. The pharmacologic actions that have been re‐
ported as likely to be involved in the drug's antirheumatic effects include suppression of cy‐
tokine production in the synoviocytes [43], suppression of antibody production from B-
lymphocytes [44,45], and suppression of osteoclast differentiation [46]. According to a recent
report, the effect of this drug in inhibiting Akt signals is involved in the suppression of anti‐
body production from B-lymphocytes and the suppression of cytokine production by the
synoviocytes [47,48]. Numerous adverse reactions including renal disorders and skin disor‐
ders are known, with serious adverse reactions including interstitial pneumonia and hema‐
tological disorders, and therefore patients must be watched closely. When used for the
treatment of RA, BUC is administered at an initial dose of 100 mg/day, with a gradual in‐
crease up to 300 mg/day if efficacies are insufficient.
9. Tacrolimus (TAC)
TAC was initially sold as a drug for suppression host rejection of grafts. In 2005, its indica‐
tion was expanded to encompass treatment of RA. The known effects of TAC include inhibi‐
tion of the proliferation and differentiation of T lymphocytes involved in persistence of RA-
associated inflammation and suppression of inflammatory cytokine production. The effect
of this drug on RA is not strong when used as mono-therapy. It shows excellent efficacy
when used as an additional drug in combination therapy for patients who have insufficient
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response to MTX alone [49]. In Western countries, this drug is not used frequently because
the results of clinical trials of mono-therapy have been unsatisfactory, and the ACR has not
advocated the use of TAC as a means of treating RA because of its insufficient efficacy [18].
Adverse reactions to TAC include headache, renal disorders, hyperglycemia, hyperurice‐
mia, hypertension, and others. Since TAC is less likely to affect the respiratory system, it is
occasionally used in patients who have respiratory complications. When used for the treat‐
ment of RA, this drug is usually administered at a dose of 3 mg/day, and at 1.5 mg/day in
elderly patients.
10. Gold Compound
Two formulations of gold compound (injection and oral-dose preparations) are available.
The efficacy and safety profiles partially differ between these 2 forms. Injection is performed
intramuscularly once weekly at an initial dose of 50 mg/week, followed by maintenance
dosing (once every 2 to 4 weeks). The response rate is relatively high, but effects are usually
not evident until after 3 to 6 months. The frequency of discontinuation of treatment due to
adverse reactions is high, with skin and mucosal disorders being the most frequent causes
for discontinuation. Adequate monitoring for proteinuria and renal dysfunction is necessa‐
ry, and care is also needed regarding hematological disorders, since leukopenia, thrombocy‐
topenia, and hypoplastic anemia can develop following treatment with this drug. The oral-
dose preparation is administered twice daily at a dose of 3 mg/dose. The efficacy of the oral-
dose preparation is less than that of the injection and takes up to 9 months to appear.
Adverse reactions to the oral-dose preparation are akin to those of the injection, although
the incidence of renal and hematological disorders is slightly lower with the oral prepara‐
tion.
11. Azathioprine
This drug is a purine analog and is shown to exert immunosuppressive effects by antimitot‐
ic action induced by inhibiting the synthesis of DNA and proteins. The efficacy of this drug
against RA is comparable to that of other slow-acting drugs. Adverse reactions to azathio‐
prine include gastrointestinal disorders, liver disease, leukopenia, and others.
12. Cyclosporine
Cyclosporine is an immune suppressor that is generally used as means of suppressing host
rejection of grafts. This drug suppresses the production and physiological actions of interleu‐
kin-2 and lymphocyte growth factor, taking 6 to 12 weeks before manifestation of its efficacy
against RA. Frequently observed adverse reactions to this drug include renal disorders, hyper‐
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tension, gingival thickening, increased body hair, and others. Cyclosporine is recommended
only for treatment of severe and advanced RA that has failed to respond to other drugs.
13. Cyclophosphamide
Cyclophosphamide is an alkylating agent with nonspecific cytotoxic activity. It suppresses
the immune system by disturbing lymphocytes in a nonspecific manner. This dug has been
positioned to play an important role in the treatment of SLE and vasculitis. It is rarely used
for patients with RA because of strong adverse effects.
14. Changes in the position of small molecule DMARDs in the treatment
of RA
According to the pyramid therapy [1] model that had been established by the beginning of
the 1990s, RA treatment focused on alleviation of symptoms (pain, inflammation, etc.) with
the use of NSAIDs and steroids at sufficiently high doses. Use of antirheumatic drugs was
confined to cases with marked progression of bone erosion and other severe manifestations.
It was noted that in cases requiring treatment by NSAIDs and steroids inflammation ap‐
peared to subside gradually by means of burnout over time. However, the RA itself re‐
mained unchanged and bone destruction continued to advance, accompanied by
progression of joint dysfunction [50]. The primary drug therapy in those days played only
the role of suppressing symptoms (i.e., pain and swelling), and it could not prevent progres‐
sion of bone destruction, joint dysfunction, and other morbidity.
This situation changed dramatically during the period from the latter half of the 1990s to the
2000s. MTX had become clinically available for use in the treatment of RA in the 1980s to
1990s, and subsequently began to be used extensively as an anchor drug for the treatment of
RA [2,3,4]. The term anchor drug refers to any drug used as a “protagonist” in the treatment
of RA. In the management of RA, MTX was positioned as a drug whose necessity would be
determined on the basis of the severity of the disease, and which would become indispensa‐
ble in cases where the disease severity exceeded a certain level. After the mid-1990s, a series
of data were published that provided new evidence of the efficacy of combined DMARD
therapy (2 or 3 DMARDs) as compared to DMARD mono-therapy, stimulating active adop‐
tion of DMARD combination therapy. During this time, MTX also came to be positioned as a
key drug in combination therapy, and to date, the prominence MTX as an anchor drug has
not changed [5]. From the late 1990s to the 2000s, biologics, primarily TNF inhibitors, began
to be introduced clinically as drugs expected to improve long-term prognosis and to main‐
tain physical function [6,7,8], and by the 2000s, these events had led to an acceleration in
some countries to revise existing treatment guidelines and diagnostic criteria for RA, which
was accompanied by a shift of the focus of treatment from anti-inflammatory analgesia and
delay of disease progression to achievement of disease remission and prevention of progres‐
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sion. The RA management guidelines that were published by the ACR in 2002 positioned
DMARDs as first-line drugs for RA treatment, which were to be started within 3 months af‐
ter disease onset, while positioning NSAIDs and steroids as auxiliary drugs for symptoms
such as pain and inflammation [9]. These guidelines additionally recommended switching
patients to different DMARDs if the initially prescribed DMARDs failed to exert sufficient
efficacy within 3 months of the initiation of treatment. This guideline clearly positioned
MTX as an anchor drug, allowing clinicians to acknowledge that a current framework of RA
treatment had been decided at that time. It was also recommended by this guideline that bi‐
ologics should be used in cases that were failing to respond well to treatment with
DMARDs, including MTX. We may infer that in their early days, the clinical use of biologics
was confined to intractable cases because this class of drug had not yet been evaluated in a
sufficient number of cases (Figure 1).
During the period from the late 1990s to 2000s, as a series of new biologics were introduced
and the clinical trial data on these drugs accumulated, it was suggested by some of these
data that active use of biologics beginning soon after disease onset might be advantageous
in some patients in terms of efficacy of long-term RA management, notably when focusing
on the effects of biologics in suppressing progression of bone destruction and physical dys‐
function, which were not seen with small molecule DMARDs [11,12]. In some patients, pri‐
marily those anticipated to have poor prognoses and those with rapidly progressive RA,
biologics began to replace small molecule DMARDs. In 2008, noting this trend, the ACR
made public a new recommendation on RA treatment that stated that the use of TNF inhibi‐
tors should be recommended as an option for first-line
Figure 1. Guidelines for the management of rheumatoid arthritis: 2002 Update
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medication for patients with high disease activity at 3 months to less than 6 months after
disease onset, and patients with high disease activity and factors associated with poor prog‐
nosis at less than 3 months after disease onset [18] (Figure 2). Campaigns promoting a better
long-term prognosis by earlier start of treatment with biologics based on these develop‐
ments and bolstered by financial programs that assisted patients with out-of-pocket pay‐
ments for biologics created stiff competition over biologics among manufacturers, and has
reportedly promoted an increase in the quantity of biologics used for RA treatment. Howev‐
er, there are still many open issues surrounding biologics, including the high percentage of
patients who fail to respond to biologics [14], the high price that causes large burdens on
individuals and society [15], and the risk of serious adverse reactions such as infection
[16,17]. The use of DMARDs, primarily in combination therapy, has also fallen under re‐
newed scrutiny following publication of new studies. These events may stimulate further re‐
vision of the current guidelines/guidance on RA treatment.
Restriction of the use of biological preparations due to the necessity of out-of-pocket pay‐
ment of their cost
Figure 3 illustrates the sales of 3 biological TNF antagonists per 100,000 populations in each
country. It shows that biologics are used a lot in European countries such as Norway and
Sweden. In these countries, patients are usually required to pay no money or only very small
amounts (less than 1,000 yen) as out-of-pocket payment during each visit to a medical facili‐
ty [10,51]. The consumption tax rate is high (about 20 to 30%) in these countries, and a large
portion of the consumption tax collected is spent for social welfare, including medical ex‐
pense. This is the reason why the out-of-pocket payment is small for patients in these countries.
Figure 2. American College of Rheumatology 2008 recommendations on indications for the use of biologic Disease-
modifying antirheumatic drugs in patients with RS <6 months
The United States, on the other hand, is the only developed country having no universal
public health insurance. Excluding Medicare and Medicaid for elderly people, physically
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handicapped citizens and low-income families, healthcare in the United States depends on
private sector insurance not mandatory for individual citizens. The premium for private
health insurance is high, and a high percentage of uninsured people is often highlighted as a
social problem in this country. For individuals covered by health insurance, the out-of pock‐
et payment is not very large, although it varies depending on the insurance plan selected by
individuals. Furthermore, unique campaigns by pharmaceutical companies are available in
the United States, promoting the treatment with biologics. Under such campaigns, a majori‐
ty of individual patient drug cost will be borne by the manufacturer to take over if the pa‐
tients agree to treatment with specific drugs for a certain period of time and are registered
with the treatment programs (RemiStart, Enbrel Support, My Humira, etc).
In Japan, however, annual out-of-pocket payment amounting to about 400,000 to 500,000
yen (about 5000 to 6500 dollars) is needed for many patients receiving treatment with bio‐
logics, excluding some patients covered by social welfare programs for reduction of out-of-
pocket payment of healthcare expenses (specific physically handicapped individuals,
individuals covered by poverty program, and so on). (Japan and Korea are the only coun‐
tries belonging to the OECD where individuals covered by health insurance are required to
make out-of-pocket payment to bear 30 % of health care costs.) This amount of out-of-pocket
payment is about 25 times as large as the out-of-pocket payment needed for conventional
DMARDs. There are patients who give up receiving treatment with biologics because they
cannot afford to pay the expense [51].
Figure 3. Sales of three biologics TNF antagonists per 100,000 population (A) and Price index and the percentage of
patients using biologics TNF antagonist in the world in 2006 (B)
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15. Current standard of care for RA
It has been shown that intervention with biologics at early stages of RA is expected to con‐
trol the disease activity and suppress subsequent joint destruction, thus facilitating remis‐
sion of RA, biologics free and cure [52]. However, according to the Best study [53], the long-
term outcome of treatment differs little among different treatment strategies. It has thus
been suggested to be more important to practice tight control through adjusting treatment
flexibly depending on the disease activity in individual cases, instead of selecting biologics
from the beginning (Figure 4).
In 2012, the ACR published the "2012 Update of the 2008 American College of Rheumatolo‐
gy Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic
Agents in the Treatment of Rheumatoid Arthritis," and recommended separate methods of
treatment for patients at early stages of RA (less than 6 months after onset) and patients with
established RA (6 months or more after onset) [18]. According to the revised guidelines, in‐
tervention with biologics is recommended for cases of established RA if the RA cannot be
adequately controlled with recommended DMARD therapies (Figure 5). The guidelines also
state that use of TNF inhibitors deserves to be considered even in patients with early stage
RA if factors associated with poor prognosis are present and the disease activity is high, al‐
though it seems to be accepted that biologics have become a mode of treatment that is con‐
sidered, as a rule, only in cases where the activity of RA cannot be controlled sufficiently by
adequate treatment with small molecule DMARDs, including MTX.
Figure 4. Seven year Results of DAS steered treatment in the BeSt Study: clinical and radiological outcome
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Under the National Health Service (NHS) in the United Kingdom, in which prescription
payments for individual patients are borne by the government, RA treatment is guided by
the recommendations of the National Institute for Health and Clinical Excellence (NICE)
[54]. The procedure for treatment under this system is more concrete than the ACR recom‐
mendations, and permits moving to therapy with biologics (anti-TNF preparations) or tocili‐
zumab in cases that are poorly controlled despite attempts of treatment with DMARD
combination therapy including MTX, even at the highest possible dose levels (Figure 6).
However, permission for the use of these biologics under the British system requires that the
manufactures bear any individual drug costs exceeding £9296 per year.
16. Comparison between small molecule DMARDs combination therapy
and biologics plus MTX combination therapy
Regarding drug therapy at early stages of RA, the two-year data were recently reported on
multicenter comparative clinical studies of three small molecule DMARDs combination
therapy (MTX + SASP + HCQ) and biologics plus MTX combination therapy in the United
States (TEAR study) [55] and Sweden (Swefot trial) [56]. In the TEAR study, the outcome as
to DAS28-ESR did not differ between the oral triple therapy and the etanercept plus MTX
combination therapy (first endpoint), and ACR20 and 50 was observed no difference be‐
tween the two groups. The only significant difference was between two groups for ACR70
(Figure 7). In the
Figure 5. update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying
antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
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Figure 6. Summary of the management of rheumatoid arthritis in National Institute for Healt and Clinical Exellence
guideline for rheumatoid arthritis
Swefot trial, there was no difference between the three small molecule DMARDs combina‐
tion therapy group and the infliximab plus MTX combination therapy group in terms of
ACR 20, 50 or 70 or EULAR good/moderate response. The TEAR study revealed no differ‐
ence between the oral triple therapy group and the biologics plus MTX combination therapy
group from the 12th month on after the start of treatment, while the Swefot trial disclosed
higher efficacy of biologics plus MTX combination therapy during the first 6-12 months of
treatment, followed by gradual disappearance of the inter-group difference during the two-
year follow-up period. Also according to the long-term data from Best study conducted in
the Netherlands [53], there was no significant difference in clinical improvement or the de‐
gree of bone/joint destruction on radiographic examination between Group 3 (treatment
started with 3 drugs, MTX + SASP + steroid) and Group 4 (treatment started with biological
preparations).
Regarding the degree of bone/joint destruction on radiographic examination, both TEAR
study and Swefot trial demonstrated significant reduction in the biologics plus MTX combi‐
nation therapy group, with the inter-group difference being 1-2 in terms of total Sharp
Heijde score (full point: 448) of the mean progression of destruction per year relative to the
baseline at the start of treatment. It might be thought that it is questionable to use the expen‐
sive biologics as the initial means of intervention into RA if only such slight suppression of
bone/joint destruction on X-ray can be achieved.
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Figure 7. Results from the TEAR trial: oral triple Therapy vs. etanercept plus methotrexate in early RA (A): Observed
DAS28-ESR,(B): Percentage of participants in TEAR achieving ACR20, 50, and 70 criteria at time of step-up at 6 months
and at the 2 year conclusion of the study.
17. Three small molecule DMARD combination therapy in Japan
(JaSTAR study)
The ACR recommendation and the NICE (U.K.) guidance state that the three DMARDs com‐
bination therapy should be applied before treatment with biologics [18,54]. In Japan, HCQ
has not been approved for use in the treatment of RA because of adverse reactions. The
three drug combined therapy (MRX + SASP + HCQ) is therefore not practically possible in
Japan. We thus started a multicenter comparative clinical study on treatment of early stage
RA with three small molecule DMARD combination therapy and biological TNF antagonists
plus MTX combination therapy, involving nationwide 32 facilities of rheumatologist in Ja‐
pan (JaSTAR study: Japan Strategic Treatment of Aggressive RA) [57].
The DMARDs used in the JaSTAR study were MTX, SASP and Bucillamine (Buc). Buc was
used instead of HCQ for the following reasons:
1. Buc is a DMARD used frequently in Japan; and
2. this combination of three drugs with Recommendation Level “A” according to the
Guidelines of the Ministry of Health, Labour and Welfare seemed to be appropriate for
this study [41].
To date, case registration has been completed, achieving the targeting number (160 cases),
and each patient enrolled to the study is now under follow-up. Interim analysis of the data
during the first 6 months revealed a similar DAS28 remission rate between the three
DMARDs combination therapy group and the biological TNF antagonists plus MTX combi‐
nation therapy group (Figure 8). The treatment continuation rate among the 33 cases where
one-year data have been analyzed was superior over the anti-TNF therapy continuation rate
previously reported from the DANBIO registry [68] (Figure 9). We are looking forward to
the results from final data analysis.
Small Molecule DMARD Therapy and Its Position in RA Treatment
http://dx.doi.org/10.5772/53320
179
Figure 8. Distribution of disease activity of patients before and after treatment for 6 monts in JaSTAR Study
Figure 9. Cumulative continuation rate of triple DMARDs combination therapy in JaSTAR Stady, Cumulative continua‐
tion rate of TNF inhibitors in DANBIO study was superimposed.
18. Introduction of new small molecule DMARDs for RA treatment
It is known that among the drugs currently used for treatment of RA, those targeted at cyto‐
kines, all of which fall under the category of biologics, have yielded particularly favorable
outcomes. However, unless the open issues mentioned above are resolved, it is unlikely that
biologics will play a central role in the treatment of RA. In 2012 and 2013, there were 2 new
DMARDs scheduled for introduction for RA treatment. One of them, tofacitinib, has been
developed with attention focused on the role of cytokines in RA. If tofacitinib is shown in
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clinical practice to be a means of RA treatment possessing both the advantages of biologics
and the advantages of small molecule DMARDs, it is expected that another paradigm shift
will occur in RA management. The 2 new DMARDs are described in further detail below.
19. Tofacitinib
Tofacitinib has been developed as a drug for treatment of RA. It is shown to be an inhibitor
of Janus kinase 3 (JAK3), an enzyme reported to be involved in cytokine receptor signal
transduction. To date, tofacitinib has been experimentally shown to suppress all JAKs (1
through 3), rather than manifesting selective action against any particular JAK. Tofacitinib
suppresses cytokines through inhibition of JAK-stat signals. In May 2012, the US FDA is‐
sued an approval recommendation for the use of this drug in adults with moderate or se‐
vere RA. According to the results of clinical trials, treatment with tofacitinib for 3 months
achieved a semi-favorable (about 50%) ACR20 in patients who were responding poorly to
TNF inhibitor treatment, with a placebo group achieving about 25%. Clinical trials have also
been conducted for tofacitinib as a first-line drug, and in patients responding poorly to
MTX, each yielding favorable outcomes. This drug is therefore reported to be promising not
only as an additional option during biologic therapy but also as a first-line drug. Adverse
reactions that require caution are elevations in blood cholesterol levels and neutrophilia.
20. Iguratimod
Iguratimod was formulated as a COX2 inhibitor and was later found to have immune mod‐
ulating activity. It was thus developed as a DMARD. Iguratimod has been shown to be use‐
ful in combination with other drugs in patients failing to respond well to MTX. Elevation in
liver enzymes is known as an adverse reaction.
21. Conclusion
As detailed herein, small molecule DMARDs have played a central role in treatment of RA
since before the introduction of biologics, and it has been shown that modification of
DMARD regimens (e.g., consideration of combination therapy beginning soon after disease
onset) can improve the long-term prognosis, allowing small molecule DMARDs to serve as
valid alternatives for biologics in RA treatment. While it is also known that treatment with
biologics is useful in cases of high activity RA, even in these cases, there may be patients for
whom combination therapy using existing DMARDs should be considered before introduc‐
tion of biologics. Further changes in the paradigm of RA treatment are expected pending re‐
sults of clinical use of new oral-dose small molecule DMARDs that have shown effects
similar to both biologics and small molecule DMARDs.
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